A practical reference on fatty diacid: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
GLP-1 receptors are expressed on pancreatic beta cells, in the gut, and in several brain regions. Receptor activation raises cyclic AMP, enhances glucose-dependent insulin secretion, and suppresses glucagon release when blood glucose is high. Effects on gastric emptying and on hypothalamic appetite circuits reduce energy intake. Because insulin release remains glucose-dependent, the risk of hypoglycemia is low when the drug is used alone. The precise contribution of each pathway to body weight change in humans remains an area of active investigation.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, a gut hormone released after meals. Its backbone retains the GLP-1 sequence but incorporates two substitutions that slow enzymatic breakdown by dipeptidyl peptidase-4. A short polyethylene glycol linker and a C18 fatty diacid are attached to the peptide chain, allowing the molecule to bind serum albumin and remain in circulation far longer than the native hormone. The result is a circulating half-life measured in days rather than the minutes typical of endogenous GLP-1.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Routine characterisation of the peptide relies on reversed-phase high-performance liquid chromatography, often paired with ultraviolet detection near 214 nanometres. Related substances such as deamidated, oxidised, and truncated sequences elute at characteristic positions and are quantified by area percentage. Electrospray ionisation mass spectrometry confirms the molecular mass and can resolve some closely related variants. Peptide mapping after enzymatic digestion provides sequence-level verification and is useful when a full identity profile is required. Method parameters such as column chemistry, gradient, and mobile-phase pH influence the separation and must be reported alongside results.
Storage guidance for the finished injectable product distinguishes the unused state from the in-use state. Before first use, pens are kept refrigerated between 2 and 8 degrees Celsius, protected from light, and never frozen, since freezing can disrupt the peptide or the device. After first use, label instructions in several markets permit storage at room temperature up to about 30 degrees Celsius for a limited number of days. Solid research-grade material is normally held at or below minus 20 degrees Celsius, often with desiccant, and allowed to equilibrate before opening.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
Polymeric monoliths as they exist today were developed independently by three different labs in the late 1980s led by Hjerten, Svec, and Tennikova. Simultaneously, bioseparations became increasingly important, and monolith technologies proved beneficial in biotechnology separations. Though industry focus in the 1980s was on biotechnology, focus in the 1990s shifted to process engineering. While mainstream chromatographers were using 3μm particulate columns, sub-2μm columns were in research phase. The smaller particles meant better resolution and shorter run times; there was also an associated increase in backpressure. In order to withstand the pressure, a new field of chromatography came into being: UHPLC or UPLC- ultra high pressure liquid chromatography. The new instruments were able to endure pressures of up to 15,000 pounds per square inch (1,000 bar), as opposed to conventional machines, which, as previously state, can hold up to 5,000 pounds per square inch (340 bar). UPLC is an alternative solution to the same problems monolithic columns solve. Similarly to UPLC, monolith chromatography can help the bottom line by increasing sample throughput, but without the need to spend capital on new equipment. In 1996, Nobuo Tanaka, at the Kyoto Institute of Technology, prepared silica monoliths using a colloidal suspension synthesis (aka “sol-gel”) developed by a colleague. The process is different from that used in polymeric monoliths. Polymeric monoliths, as mentioned above, are created in situ, using a mixture of monomers and a porogen within the column tubing.
17 February Freud under Analysis, historian Peter Gay; psychiatrist Joseph Wortis; the Freud Museum in north-west London; his friend Josef Breuer; his 1895 book Studies on Hysteria; psychologist Frank Sulloway; psychology writer Jeffrey Moussaieff Masson; psychiatrist Jacob Arlow; his 1905 Three Essays on the Theory of Sexuality; the Berlin Psychoanalytic Institute opened in 1920, and he had founded the Deutsche Psychoanalytische Gesellschaft; Abraham Brill; in October 1952 psychologist Hans Eysenck wrote in the Journal of Consulting and Clinical Psychology; Hungarian psychiatrist Thomas Szasz; the Yale Child Study Center; psychologist Jerome Kagan; Francis Crick disputed Freud; Freud moved to England in 1938. A US production, produced by Ben Gooder, directed by Susanne Simpson, made by WGBH and Uden Associates 23 July Mission to Mars, astrogeologist Harold Masursky; Carol Stoker from NASA Ames; planetary geologist Alfred McEwen; German Jesco von Puttkamer and how the space station would be ready by 1994; Gentry Lee of JPL; Jonathan Eberhart and his song about the atmosphere of Mars. Narrated by Martin Jarvis, produced by Patrick Uden, made by Uden Associates 30 July Playing with Fire, about the Bradford City stadium fire on Saturday 11 May 1985; it featured the Woolworths fire of 8 May 1979, in central Manchester. Produced by Michael Blakstad, directed by Patrick Fleming, made by Workhouse Productions
== Evolution of neuropeptide signaling == Peptides are ancient signaling systems that are found in almost all animals on Earth. Genome sequencing reveals evidence of neuropeptide genes in Cnidaria, Ctenophora, and Placozoa, some of the oldest living animals with nervous systems or neural-like tissues. Recent studies also show genomic evidence of neuropeptide processing machinery in metazoans and choanoflagellates, suggesting that neuropeptide signaling may predate the development of nervous tissues. Additionally, Ctenophore and Placozoa neural signaling is entirely peptidergic and lacks the major amine neurotransmitters such as acetylcholine, dopamine, and serotonin. This also suggests that neuropeptide signaling developed before amine neurotransmitters.
Sources: en.wikipedia.org
We will keep pressing. We will keep pushing, keep advancing, no quarter, no mercy for our enemies. Yet some in this crew, in the press, just can't stop. Allow me to make a few suggestions. People look up at the TV and they see banners, they see headlines. I used to be in that business. And I know that everything is written intentionally.For example, a banner or a headline: "Mideast war intensifies," splashing on the screen the last couple of days, alongside visuals of civilian or energy targets that Iran has hit, because that's what they do. What should the banner read instead?How about, 'Iran increasingly desperate,' because they are. They know it and so do you, if it can be admitted. Or more fake news from CNN, "reports that the Trump administration underestimated the Iran war's impact on the Strait of Hormuz" – patently ridiculous, of course. For decades, Iran has threatened shipping in the Strait of Hormuz.This is always what they do, hold the strait hostage. CNN doesn't think we thought of that. It's a fundamentally unserious report. The sooner David Ellison takes over that network, the better.Another example of a fake headline that I saw yesterday, "war widening." Here's a real headline for you, for an actual patriotic press: how about, 'Iran shrinking, going underground'? You see, Iran's leaders are hiding in bunkers and moving into civilian areas. The only thing that is widening is our advantage, not to mention our Gulf partners stepping up even more, now going on the offense, and have always been with us on the defense with collective and integrated air defenses.
=== WEAA 88.9 FM === WEAA 88.9 is the NPR-affiliated public radio station of Morgan State University, and a service of the university's School of Global Journalism and Communication. It began broadcasting on January 10, 1977, with call letters standing for "We Educate African Americans." Broadcasting since 1977, WEAA 88.9 operates independently and attracts support from public donors, underwriters, and grant-makers.
=== Cell culturing === Peptide scaffolds formed from LEGO peptides have been used extensively for 3D cell culturing as they closely resemble the porosity and the structure of extra-cellular matrices. These scaffolds have also been used in cell proliferation and differentiation into desired cell types. Experimentations with rat neurons demonstrated the usefulness of LEGO peptides in cell culturing. Rat neurons that were attached to the peptides projected functional axons that followed the contours of the peptide scaffolds.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.